Description
Gi-6207 is an investigational drug being studied by ImmunityBio, Inc. It is currently in Phase 1 clinical trials for colorectal cancer (CRC). This trial (NCT03563157), called QUILT 3.071, is evaluating Gi-6207 as part of a vaccine approach (NANT CRC Vaccine) in patients with metastatic CRC who have already received standard treatments. The trial is comparing this vaccine approach to regorafenib, a standard chemotherapy drug for advanced CRC. Gi-6207 is being investigated in patients whose tumors have specific genetic changes (EGFR or VEGF mutations). It is important to remember that Gi-6207 is not yet approved for treating CRC and is still under investigation to determine its safety and effectiveness.
Mechanism of Action
The specific mechanism of action for Gi-6207 is being investigated in clinical trials. It is being studied as part of a vaccine strategy designed to stimulate the immune system to target cancer cells. The NANT CRC Vaccine approach aims to activate the immune system against the patient's cancer.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Category | Other Medications |
 EMA Status | Not submitted to EMA |
 Spain Access | Not available |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.